Condition
Major Depression Moderate
Total Trials
6
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Recruiting3
Not Yet Recruiting1
Enrolling By Invitation1
Terminated1
Clinical Trials (6)
Showing 6 of 6 trials
NCT07503002Phase 1Not Yet RecruitingPrimary
Shortened LSD Intervention for Major Depressive Disorder
NCT07748091RecruitingPrimary
EEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT
NCT07740694RecruitingPrimary
EEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT
NCT07146269Not ApplicableEnrolling By InvitationPrimary
Virtual Reality-Augmented At-Home tDCS for Major Depression
NCT07140575Not ApplicableRecruitingPrimary
rTMS for Youth Inpatients With Depression
NCT03254342Terminated
MRS and Medication Response: A Pilot Study
Showing all 6 trials